Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cisplatin/vinblastine - Intensity Therapeutics

Next Previous
Drug Profile

Cisplatin/vinblastine - Intensity Therapeutics

Alternative Names: Cisplatin/vinblastine sulfate; INT 230-6; PORT-1

Latest Information Update: 27 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intensity Therapeutics
  • Developer Intensity Therapeutics; Ottawa Hospital Research Institute
  • Class Antineoplastics; Platinum complexes; Small molecules; Vinca alkaloids
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Solid tumours

Most Recent Events

  • 14 Mar 2024 Intensity Therapeutics plans a phase II/III INVINCIBLE-4 trial for Triple-negative breast cancer, (Neoadjuvant therapy) in mid-2024 (Intensity Therapeutics pipeline, October 2023)
  • 03 Jan 2024 Intensity Therapeutics plans a phase III INVINCIBLE-3 trial for Soft tissue sarcoma (Metastatic disease, Late stage disease, Second-line therapy or greater) in first half of 2024 (NCT06263231)
  • 03 Jan 2024 The US FDA approves IND application for cisplatin/vinblastine in Soft tissue sarcoma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top